Autoimmune & Rheumatology System, Protocol 5/5 — completing the Autoimmune & Rheumatology System.
Cross-Reference Notice
Diffuse alveolar hemorrhage (DAH) has a full dedicated protocol in the Respiratory System, reflecting its primary clinical presentation as an acute hypoxemic respiratory failure syndrome requiring pulmonology/critical care-led diagnosis and management.
See: Diffuse Alveolar Hemorrhage (Respiratory System) for the complete protocol, covering:
- The progressively-bloodier bronchoalveolar lavage return as the confirmatory diagnostic technique
- The full ANCA vasculitis subtype comparison (GPA, MPA, EGPA) and anti-GBM (Goodpasture) serology
- RAVE and MAINRITSAN trial evidence for rituximab vs cyclophosphamide induction and maintenance therapy
- PEXIVAS trial evidence and the nuanced, selective role of plasma exchange
- ECMO candidacy despite active pulmonary bleeding, with modified anticoagulation strategy
Relevant cross-links from this Autoimmune & Rheumatology System:
- Pulmonary-Renal Syndrome (this system) is the combined pulmonary-plus-renal presentation of the SAME underlying vasculitides that cause isolated DAH — read together for the complete picture when both organ systems are involved
- Catastrophic Antiphospholipid Syndrome (this system) lists DAH as a recognized pulmonary manifestation
- HLH and Macrophage Activation Syndrome (this system) for the related hyperinflammatory autoimmune emergency spectrum
This completes the Autoimmune & Rheumatology System (5/5 protocols, with Diffuse Alveolar Hemorrhage maintained as a single authoritative protocol in the Respiratory System rather than duplicated here).